// App-Quantinova.ai

TCT-3 : Outcomes in STEMI patients treated with clopidogrel or prasugrel: A propensity adjusted analysis from the INFUSE-AMI Trial

Researchers

Presenter

  • Keith G. Oldroyd

Principal Investigators

  • Sorin Brener

  • Akiko Maehara

  • Magdi El-Omar

  • Bernhard Witzenbichler

  • Ke Xu

  • Roxana Mehran

  • C. Michael Gibson

  • Gregg W. Stone

Medical Centers

  • Mount Sinai Hospital, New York, NY

  • Charite Campus Benjamin Franklin, Berlin, Germany.

  • University of Glasgow, Glasgow, United Kingdom

  • Cardiovascular Research Foundation and Columbia University Medical Center, New York, United States

  • Cardiovascular Research Foundation, Orangeburg, NY

  • Department of Pediatrics, New York Methodist Hospital, Brooklyn, NY

  • Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA

  • Cardiovascular Research Foundation, Orangeburg, NY

  • Manchester Heart Centre, Mancheter, United Kingdom

Locations

  • United States

  • Germany

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Cardiovascular (CVS)

  • Blood/haematological Diseases

  • Pulmonary/Respiratory Diseases

Disease

  • Acute Coronary Syndromes

  • Venous thrombosis

Biomarkers

  • N/A

Drug/Treatment

  • Bivalirudin

  • Clopidogrel bisulfate

  • Abciximab

  • Prasugrel

  • Heparin

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved